Literature DB >> 1309923

RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence.

K M Chumakov1, L P Norwood, M L Parker, E M Dragunsky, Y X Ran, I S Levenbook.   

Abstract

Mutant analysis by polymerase chain reaction and restriction enzyme cleavage (MAPREC) was used to study sequence heterogeneity and stability in attenuated poliovirus type 3 at positions in which the vaccine virus differs from its wild-type progenitor. Of seven genomic positions tested, only two (positions 472 and 2493) show nucleotide heterogeneity. Propagation of the vaccine virus in cell cultures leads to rapid selection of virus with reversions at these two positions of the genome. The relative abundance of reversions at position 472 correlates with the results of monkey neurovirulence tests, while the mutation at position 2493 is not directly associated with neurovirulence of the virus in monkeys. Instead, the abundance of mutations at the latter position correlates with the source of the seed virus and its passage level. These results further indicate that MAPREC at position 472 can be used to assess the quality of poliovirus type 3 vaccine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309923      PMCID: PMC240798     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  5 in total

1.  Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine.

Authors:  K M Chumakov; L B Powers; K E Noonan; I B Roninson; I S Levenbook
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

2.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors:  G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

Authors:  H Toyoda; M Kohara; Y Kataoka; T Suganuma; T Omata; N Imura; A Nomoto
Journal:  J Mol Biol       Date:  1984-04-25       Impact factor: 5.469

4.  Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.

Authors:  D M Evans; G Dunn; P D Minor; G C Schild; A J Cann; G Stanway; J W Almond; K Currey; J V Maizel
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

5.  Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b.

Authors:  G Stanway; P J Hughes; R C Mountford; P Reeve; P D Minor; G C Schild; J W Almond
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

  5 in total
  15 in total

1.  Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture.

Authors:  K Matsuura; M Ishikura; H Yoshida; T Nakayama; S Hasegawa; S Ando; H Horie; T Miyamura; T Kitamura
Journal:  Appl Environ Microbiol       Date:  2000-11       Impact factor: 4.792

2.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

3.  Quantitative mutant analysis of viral quasispecies by chip-based matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry.

Authors:  G Amexis; P Oeth; K Abel; A Ivshina; F Pelloquin; C R Cantor; A Braun; K Chumakov; A Brau
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

4.  Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.

Authors:  Alexander Neverov; Konstantin Chumakov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

5.  Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina.

Authors:  Judith E Mueller; Maël Bessaud; Q Sue Huang; Laura C Martinez; Patricia A Barril; Viviane Morel; Jean Balanant; Judy Bocacao; Joanne Hewitt; Brad D Gessner; Francis Delpeyroux; Silvia V Nates
Journal:  Appl Environ Microbiol       Date:  2009-01-05       Impact factor: 4.792

6.  PCR engineering of viral quasispecies: a new method to preserve and manipulate genetic diversity of RNA virus populations.

Authors:  K M Chumakov
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.

Authors:  Michael Famulare; Stewart Chang; Jane Iber; Kun Zhao; Johnson A Adeniji; David Bukbuk; Marycelin Baba; Matthew Behrend; Cara C Burns; M Steven Oberste
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

9.  Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus.

Authors:  Majid Laassri; Bella Bidzhieva; James Speicher; Alexander G Pletnev; Konstantin Chumakov
Journal:  J Med Virol       Date:  2011-02-25       Impact factor: 2.327

10.  Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine.

Authors:  Sabine van der Sanden; Mark A Pallansch; Jan van de Kassteele; Nasr El-Sayed; Roland W Sutter; Marion Koopmans; Harrie van der Avoort
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.